ArticleScientific reports2017
One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Development, Characterization, and Validation of an MS2 Phage-Based Armored RNA Control for Schmallenberg Virus Detection.Pathogens (Basel, Switzerland) · 2026Article
- Self-Assembling Nanoparticle Enhances RNA Interference Efficiency againstJournal of agricultural and food chemistry · 2026Article
- Simplified MS2 phage-like particle production including a novel maturation protein internal fusion affinity tag.Biotechnology, biotechnological equipment · 2025Article
- Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.Nanomedicine (London, England) · 2024Review
- Unified access to up-to-date residue-level annotations from UniProtKB and other biological databases for PDB data.Scientific data · 2023Article
- One-plasmid double-expression system for preparation of MS2 virus-like particles packaging SARS-CoV-2 RNA.Frontiers in cellular and infection microbiology · 2023Article
- Simple Low-Cost Production of DNA MS2 Virus-Like Particles As Molecular Diagnostic Controls.GEN biotechnology · 2022Article
- Programmable polymorphism of a virus-like particle.Communications materials · 2022Article
- A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics.Nature communications · 2020Article
- Bacteriophage MS2 displays unreported capsid variability assembling T = 4 and mixed capsids.Molecular microbiology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MS2 phage-like particles (MS2 PLP) are artificially constructed pseudo-viral particles derived from bacteriophage MS2. They are able to carry a specific single stranded RNA (ssRNA) sequence of choice inside their capsid, thus protecting it against the effects of ubiquitous nucleases. Such particles are able to mimic ssRNA viruses and, thus, may serve as the process control for molecular detection and quantification of such agents in several kinds of matrices, vaccines and vaccine candidates, drug delivery systems, and systems for the display of immunologically active peptides or nanomachines. Currently, there are several different in vivo plasmid-driven packaging systems for production of MS2 PLP. In order to combine all the advantages of the available systems and to upgrade and simplify the production and purification of MS2 PLP, a one-plasmid double-expression His-tag system was designed. The described system utilizes a unique fusion insertional mutation enabling purification of particles using His-tag affinity. Using this new production system, highly pure MS2 PLP can be quickly produced and purified by a fast performance liquid chromatography (FPLC) approach. The system can be easily adapted to produce other MS2 PLP with different properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.